Precision Medicine Quarterly

Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.

2021-04-29T12:29:27-05:00April 29th, 2021|

Basel, April 27, 2021 - commenting on the quarter, Vas Narasimhan, CEO of Novartis, said: “Novartis growth drivers and launches continued their strong momentum with double-digit growth for Entresto, Cosentyx, Oncology growth drivers and Zolgensma. We expect Sandoz performance to stabilize, in the near-term, after a challenging quarter. Our broad pipeline of novel medicines continued [...]

Geisinger awarded $3.6 million to study genetics of cancer

2021-04-29T12:07:14-05:00April 29th, 2021|

The National Cancer Institute (NCI), part of the National Institutes of Health, has awarded a 5-year, $3.6 million contract to Geisinger to study the role of genetic variation in cancer. Researchers from Geisinger and the NCI’s Division of Cancer Epidemiology and Genetics (DCEG) will analyze genetic data from Geisinger’s MyCode Community Health Initiative, a precision [...]

Thermo Fisher Scientific Reports First Quarter 2021 Results

2021-04-29T12:05:32-05:00April 29th, 2021|

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 3, 2021. First Quarter 2021 Highlights First quarter revenue increased 59% to $9.91 billion. First quarter GAAP diluted earnings per share (EPS) increased 198% to $5.88. First quarter adjusted EPS increased 145% to $7.21. Continued significant [...]

Illumina to Donate US $60 Million in Sequencing Capabilities to Establish a Global Pathogen Genomics Initiative

2021-04-29T12:02:23-05:00April 29th, 2021|

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) has committed US $60 million in sequencing capabilities to a global pathogen genomics initiative, in partnership with the Bill & Melinda Gates Foundation and other public and private entities. The initiative expands on the Africa Pathogen Genomics Initiative (Africa PGI) announced in October 2020, and will help create [...]

Bristol Myers Squibb Reports First Quarter Financial Results for 2021

2021-04-29T12:00:12-05:00April 29th, 2021|

Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2021, which reflect continued sales growth and advancement of the company’s product pipeline across our four core therapeutic areas.“We continue to deliver solid growth, execute against our strategic priorities and make meaningful progress across our pipeline,” said Giovanni Caforio, M.D., board chair and [...]

Mission Bio Announces Yan Zhang as New CEO

2021-04-09T09:21:40-05:00April 9th, 2021|

Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced the appointment of Yan Zhang to the role of CEO. Zhang joins Mission Bio after 10 years at Thermo Fisher Scientific, where she drove above-market growth for multiple business lines, including leading the commercial organization in China for Genetic Sciences and [...]

Diagnostic Laboratory Services, Inc. (DLS) Launches New Precision Medicine Program with GenomOncology’s Pathology Workbench

2021-04-09T09:18:18-05:00April 9th, 2021|

GenomOncology, LLC announced today that Diagnostic Laboratory Services, Inc. (DLS) has selected the GenomOncology (GO) Pathology Workbench to streamline variant analysis for their next generation sequencing (NGS) in support of the Queen's Medical Center's precision medicine program. DLS, an affiliate of the Queen's Health Systems, is the largest, locally-owned clinical laboratory in Hawaii. Historically, [...]

Cancer-Killing Virus Therapy Shows Promise Against Inoperable Skin Cancers

2021-04-09T09:08:23-05:00April 9th, 2021|

Early results show that a new combination drug therapy is safe and effective against advanced skin cancer in patients who were not able to have their tumors surgically removed. The drug combination is among the first, researchers say, to demonstrate the potential value of a live common cold virus, a coxsackievirus, to infect and [...]

Invitae to acquire Genosity to accelerate access to personalized oncology testing worldwide

2021-04-09T09:02:47-05:00April 9th, 2021|

Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Genosity Inc. ("Genosity"), a genomics company offering innovative software and laboratory solutions to enable development and deployment of complex sequencing based tests. The acquisition would bring Genosity's specialized capabilities onto the Invitae platform to accelerate [...]

Magellan Rx Management and Trapelo Health to Offer Precision Oncology Platform for Next-Generation Care

2021-04-09T08:58:24-05:00April 9th, 2021|

PHOENIX and BURLINGTON, MA (April 8, 2021): Magellan Rx Management, a division of Magellan Health, Inc. (NASDAQ: MGLN), and Trapelo Health, today announced that they are collaborating to champion a more comprehensive, integrated approach to value-based care in the new era of precision oncology treatments. The collaboration combines the unique strengths of the two [...]

Go to Top